The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rapti I.N.

Hadziyannis S.J.

Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol. Hepatol 2011; 5(3):323-339

Authors:

Rapti I.N., Hadziyannis S.J.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2012;(1): 10‑23

Views: 2302

Downloaded: 39

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Rapti IN, Hadziyannis SJ. Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol. Hepatol 2011; 5(3):323-339. Russian Journal of Evidence-Based Gastroenterology. 2012;(1):10‑23. (In Russ.)

Подписка 2025 (Russian Journal of Evidence-Based Gastroenterology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata

Treatment of special populations with chronic hepatitis B infection. Expert Rev Gastroenterol. Hepatol 2011; 5(3):323-339

Authors:

Rapti I.N.

Hadziyannis S.J.

List of references:

  1. Peters M. Special populations with hepatitis B infection. Hepatology 2009; 49: S146-S155.
  2. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis. B J Hepatol 2009; 50: 227-242.
  3. Buster E.H. Hansen B.E., Buti M. et al. Peginterferon a-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46: 388-394.
  4. Rapti I., Dimou E., Mitsoula P. et al. Adding-on versus switching-to adefovir therapy in lamivudineresistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313.
  5. Yim H.J., Hussain M., Liu Y. et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-712.
  6. Fung S.K., Andreone P., Han S.H. et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43: 937-943.
  7. Lai C.L., Gane E., Liaw Y.F. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588.
  8. Sung J.J., Tsoi K.K., Wong V.W. et al. Meta-analysis: treatment of HBV infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077.
  9. Papatheodoridis G.V., Lampertico P., Manolakopoulos S., Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356.
  10. Realdi G., Fattovich G., Hadziyannis S. et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21: 656-666.
  11. Liaw Y.F., Lin D.Y., Chen T.J. et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-241.
  12. Perrillo R.P., Wright T., Rakela J. et al. A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-432.
  13. Schiff E., Lai C.L., Hadziyannis S. et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360.
  14. Yao F.Y., Terrault N.A., Freise C. et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-416.
  15. Lange C.M., Bojunga J., Hofmann W.P. et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006.
  16. Shim Y.H., Lee H.C., Kim K.M. et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182.
  17. Choe W.H., Kwon S.Y., Kim B.K et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008; 28, 814-820.
  18. Fontana R.J. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol 2010; 52: 147-149.
  19. Liaw Y.F., Sheen I.-S., Lee C.-M. et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53 (1): 62-72.
  20. Fontana R.J., Hann H.W., Perrillo R.P. et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727.
  21. Zoulim F., Radenne S., Ducerf C. Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transpl 2008; 14: S1-S7.
  22. Yeo W., Chan P.K., Zhong S. et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
  23. Yeo W., Chan T.C., Leung N.W. et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
  24. Cheng A.L., Hsiung C.A., Su I.J. et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328.
  25. Esteve M., Saro C., González-Huix F. et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365.
  26. Yeo W., Zee B., Zhong S. et al. Comprehensive analysis of risk factors associating with hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311.
  27. Marzano A., Angelucci E., Andreone P. et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
  28. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with heamatological malignancies. Br J Heamatol 2007; 136: 699-712.
  29. Wursthorn K., Wedemeyer H., Manns M. Managing HBV in patients with impaired immunity. Gut 2010; 59: 1430-1445.
  30. Barclay S., Pol S., Mutimer D. et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008; 41: 243-254.
  31. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
  32. Loomba R., Rowley A., Wesley R. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528.
  33. Hsu C., Hsiung C.A., Su I.J. et al. A revisit of prophylactic lamivudine for chemotherapyassociated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-853.
  34. Hui C.K., Cheung W.W., Au W.Y. et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with heamatological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597-1603.
  35. Lok A., McMahon B. Chronic hepatitis B: update 2009. AASLD practice guidelines. Hepatology 2009; 50: 1-36.
  36. Kim W.R., Poterucha J.J., Kremers W.K. et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968-974.
  37. Terrault N., Roche B., Samuel D. Management of the hepatitis B virus in the liver transplantation setting; a European and an American prospective. Liver Transpl 2005; 11: 716-732.
  38. Dickson R.C., Terrault N.A., Ishitani M. et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006; 12: 124-133.
  39. Gane E.J., Angus P.W., Strasser S. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
  40. Marzano A., Gaia S., Ghisetti V. et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409.
  41. Zheng S., Chen Y., Liang T. et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258.
  42. Angus P.W., Patterson S.J., Strasser S.I. et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
  43. Coffin C.S., Terrault N.A. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007; 14: Suppl. 1: 37-44.
  44. Gaeta G.B., Stornaiuolo G., Precone D.F. et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003; 39: 1036-1041.
  45. Chu C.J., Lee S.D. Hepatitis B virus/hepatitis C virus co-infection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23: 512-520.
  46. Raimondo G., Brunetto M.R., Pontisso P. et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus co-infected patients. Hepatology 2006; 43: 100-107.
  47. Hung C.H., Lee C.M., Lu S.N. et al. Combination therapy with interferon-a and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005; 20: 727-732.
  48. Liu C.J., Chen P.J., Lai M.Y. et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37: 568-576.
  49. Liu C.J., Chuang W.L., Lee C.M. et al. Peginterferon a-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.
  50. Liu C.J., Chen P.J., Chen D.S. A forgotten population with chronic hepatitis C infection: subjects coinfected with hepatitis B virus. Hepatology 2004; 40: 266.
  51. Değertekin H., Yalzin K., Yakut M. The prevalence of hepatitis d virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol 2006; 17: 25-34.
  52. Wedemeyer H., Heidrich B., Manns M.P. Hepatitis D virus infection - not a vanishing disease in Europe! Hepatology 2007; 45: 1331-1332.
  53. Liaw Y.F., Chen Y.C., Sheen I.S. et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-1029.
  54. Farci P., Mandas A., Coiana A. et al. Treatment of chronic hepatitis D with interferon-a-2a. N Engl J Med 1994; 330: 88-94.
  55. Farci P., Roskams T., Chessa L. et al. Long-term benefit of interferon a therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004; 126: 1740-1749.
  56. Erhardt A., Gerlich W., Starke C. et al. Treatment of chronic hepatitis d with pegylated interferon-a 2b. Liver Int 2006; 26: 805-810.
  57. Niro G.A., Ciancio A., Gaeta G.B. et al. Pegylated interferon a 2-b as monotherapy or in combination with ribavirin in chronic hepatitis d. Hepatology 2006; 44: 713-720.
  58. Yurdaydin C., Bozkaya H., Onder F.O. et al. Treatment of chronic d hepatitis with lamivudine vs lamivudine+ interferon vs interferon. J Viral Hepat 2008; 15: 314-321.
  59. Yurdaydin C., Wedemeyer H., Dalekos G. et al. A multicenter randomized study comparing the efficacy of pegylated interferon a-2a plus adefovir dipivoxil vs. pegylated interferon a-2a plus placebo vs. adefovir dipivoxil for the treatment of chronic delta hepatitis: the intervention trial (HID-IT). Hepatology 2006; 41: Suppl. 1: A230.
  60. Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology 2006; 44: 536-539.
  61. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: Suppl. 1: S6-S9.
  62. Puoti M., Torti C., Bruno R. et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44: S65-S70.
  63. Soriano V., Puoti M., Bonacini M. et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 221-240.
  64. Bodsworth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B carrier state. J Infect Dis 1991; 163: 1138-1140.
  65. Wang H.S., Han S.-H. B. Management of hepatitis B in special patient populations. Clin Liver Dis 2010; 14: 505-520.
  66. Alberti A., Clumeck N., Collins S. et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-624.
  67. Benhamou Y., Fleury H., Trimoulet P. et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43: 548-555.
  68. Sheldon J.A., Corral A., Rodés B. et al. Risk of selecting K65R in antiretroviralnaive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005; 19: 2036-2038.
  69. McMahon M.A., Jilek B.L., Brennan T.P. et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-2621.
  70. Sasadeusz J., Audsley J., Mijch A. et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008; 22: 947-955.
  71. Rockstroh J.K., Bhagani S., Benhamou Y. et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIVinfected adults. HIV Med 2008; 9: 82-88.
  72. Hammer S.M., Eron Jr.J.J., Reiss P. Antiretroviral treatment of adult HIV infection. JAMA 2008; 300: 555-570.
  73. Thio C.L. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49: S138-S145.
  74. Rey D., Krantz V., Partisani M. et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161.
  75. Hoofnagle J.H., Doo E., Liang T.J. et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
  76. Jochum C., Gieseler R.K., Gawlista I. et al. Hepatitis-B associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009; 80: 235-240.
  77. Tillmann H.L., Hadem J., Leifeld L. et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13 (4): 256-263.
  78. Kondili L.A., Osman H., Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004; 11: 427-431.
  79. Tassopoulos N.C., Koutelou M.G., Polychronaki H. et al. Recombinant interferon-a therapy for acute hepatitis B: a randomized, double-blind, placebocontrolled trial. J Viral Hepat 1997; 4: 387-394.
  80. Tse K.Y., Ho L.F., Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005; 43: 771-775.
  81. Terrault N.A., Jacobson I.M. Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy. Semin Liver Dis 2007; 27: Suppl. 1: S18-S24.
  82. ter Borg M.J., Leemans W.F., de Man R.A. et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15: 37-41.
  83. Nguyen G., Garcia R.T., Nguyen N. et al. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009; 29: 755-764.
  84. Shiraki K. Perinatal transmission of hepatitis B virus and its prevention. J Gastroenterol Hepatol 2000; 15: Suppl.: E11-E15.
  85. Lee C., Gong Y., Brok J. et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332: 328-336.
  86. Ranger-Rogez S., Denis F. Hepatitis B mother-to-child transmission. Expert Rev. Anti Infect Ther 2004; 2 (1): 133-145.
  87. Xiao X.M., Li A.Z., Chen X. et al. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet 2007; 96: 167-170.
  88. Xu Q., Xiao L., Lu X.B. et al. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol 2006; 12: 3434-3437.
  89. Wang Z., Zhang J., Yang H. et al. Quantitative analysis of HBV DNA level and HBeAg titre in hepatitis B surface antigen positive mother and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003; 71: 360-366.
  90. van Zonneveld M., van Nunen A.B., Niesters H.G. et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-297.
  91. Xu W.M., Cui Y.T., Wang L. et al. Lamivudine in the late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebocontrolled study. J Viral Hepat 2008; 16: 94-103.
  92. Li X.M., Yang Y.B., Hou H.Y. et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003; 9: 1501-1503.
  93. Han G., Zhao W., Cao M. et al. A prospective and open-label study for the efficacy and safety of telbivudine (LdT) in pregnancy for the prevention of perinatal transmission of hepatitis B virus (HBV) to the infants. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Disease. Abstract 212, Boston, MA, USA, 30 October - 2 November 2010.
  94. Reddy P.A., Gupta I., Ganguly N.K. Hepatitis-B vaccination in pregnancy: safety and immunogenic response in mothers and antibody transfer to neonates. Asia Oceania J Obstet Gynaecol 1994; 20: 361-365.
  95. Yang J., Zeng X.M., Men Y.L. et al. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus - a systematic review. Virol J 2008; 5: 100.
  96. Wang J., Zhu Q., Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J 2002; 115: 1510-1512.
  97. Hill J.B., Sheffield J.S., Kim M.J. et al. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002; 99: 1049-1052.
  98. Johnson M.A., Moore K.H., Yuen G.J. et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41-66.
  99. Zou H., Chen Y., Duan Z. et al. A retrospective study for clinical outcome of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Presented at: 61st Annual Meeting of the American Association for the Study of Liver Disease. Abstract 235, Boston, MA, USA, 30 October - 2 November 2010.
  100. Iorio R., Giannattasio A., Cirillo F. et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007; 45: 943-949.
  101. Sokal E.M., Conjeevaram H.S., Roberts E.A. et al. Interferon a therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114: 988-995.
  102. Jonas M.M., Little N.R., Gardner S.D. International Paediatric Lamivudine Investigator Group. Long-term lamivudine treatment of children with chronic hepatitis B: a durability of therapeutic responses and safety. J Viral Hepat 2008; 15: 20-27.
  103. Jonas M.M., Kelly D., Pollack H. et al. Safety, efficacy and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to<18 years) with chronic hepatitis B. Hepatology 2008; 47: 1863-1871.
  104. Jonas M.M., Block J.M., Haber B.A. et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology 2010; 52: 2192-2205.
  105. Liu Y.L., Kao M.T., Huang C.C. A comparison of responsiveness to hepatitis B vaccination in patients on haemodialysis and peritoneal dialysis. Vaccine 2005; 23: 3957-3960.
  106. Lapinski T.W., Flisiak R., Jaroszewicz J. et al. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005; 11: 400-402.
  107. Fontaine H., Vallet-Pichard A., Chaix M.L. et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, haemodialysis patients and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092.
  108. Kamar N., Milioto O., Alric L. et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614.
  109. Fabrizi F., Dixit V., Martin P. Meta-analysis: antiviral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther 2006; 24: 781-788.
  110. Guillevin L., Mahr A., Callard P. et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-322.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.